Literature DB >> 25488854

Diabetic nephropathy in 2014: improved cardiorenal prognosis in diabetic nephropathy.

Hans-Henrik Parving1, Peter Rossing2.   

Abstract

In 2014, key studies in the field of diabetic nephropathy highlighted the importance of albuminuria as a predictor of cardiovascular risk and showed that the incidence of renal and cardiovascular complications is decreasing. Promising efficacy data were obtained with atrasentan, whereas a trial of bardoxolone methyl led to safety concerns.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25488854     DOI： 10.1038/nrneph.2014.238

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  9 in total

1.  Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

Authors:  Dick de Zeeuw; Tadao Akizawa; Paul Audhya; George L Bakris; Melanie Chin; Heidi Christ-Schmidt; Angie Goldsberry; Mark Houser; Melissa Krauth; Hiddo J Lambers Heerspink; John J McMurray; Colin J Meyer; Hans-Henrik Parving; Giuseppe Remuzzi; Robert D Toto; Nosratola D Vaziri; Christoph Wanner; Janet Wittes; Danielle Wrolstad; Glenn M Chertow
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

2.  Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

Authors:  Pablo E Pergola; Philip Raskin; Robert D Toto; Colin J Meyer; J Warren Huff; Eric B Grossman; Melissa Krauth; Stacey Ruiz; Paul Audhya; Heidi Christ-Schmidt; Janet Wittes; David G Warnock
Journal:  N Engl J Med       Date:  2011-06-24       Impact factor: 91.245

3.  Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies.

Authors:  Roland E Schmieder; Rudolph Schutte; Helmut Schumacher; Michael Böhm; Giuseppe Mancia; Michael A Weber; Matthew McQueen; Koon Teo; Salim Yusuf
Journal:  Diabetologia       Date:  2014-07-19       Impact factor: 10.122

4.  The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.

Authors:  Dick de Zeeuw; Blai Coll; Dennis Andress; John J Brennan; Hui Tang; Mark Houser; Ricardo Correa-Rotter; Donald Kohan; Hiddo J Lambers Heerspink; Hirofumi Makino; Vlado Perkovic; Yili Pritchett; Giuseppe Remuzzi; Sheldon W Tobe; Robert Toto; Giancarlo Viberti; Hans-Henrik Parving
Journal:  J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 10.121

5.  Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.

Authors:  Dick de Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690

6.  Changes in diabetes-related complications in the United States, 1990-2010.

Authors:  Edward W Gregg; Yanfeng Li; Jing Wang; Nilka Rios Burrows; Mohammed K Ali; Deborah Rolka; Desmond E Williams; Linda Geiss
Journal:  N Engl J Med       Date:  2014-04-17       Impact factor: 91.245

7.  Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.

Authors:  John J V McMurray; Hertzel C Gerstein; Rury R Holman; Marc A Pfeffer
Journal:  Lancet Diabetes Endocrinol       Date:  2014-03-13       Impact factor: 32.069

8.  Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors.

Authors:  Gudbjörg Andrésdóttir; Majken L Jensen; Bendix Carstensen; Hans-Henrik Parving; Kasper Rossing; Tine W Hansen; Peter Rossing
Journal:  Diabetes Care       Date:  2014-03-12       Impact factor: 19.112

9.  Effect of a multifactorial intervention on mortality in type 2 diabetes.

Authors:  Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245
  9 in total
  2 in total

1.  Randomized trial of an intensified, multifactorial intervention in patients with advanced-stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan).

Authors:  Kenichi Shikata; Masakazu Haneda; Toshiharu Ninomiya; Daisuke Koya; Yoshiki Suzuki; Daisuke Suzuki; Hitoshi Ishida; Hiroaki Akai; Yasuhiko Tomino; Takashi Uzu; Motonobu Nishimura; Shiro Maeda; Daisuke Ogawa; Satoshi Miyamoto; Hirofumi Makino
Journal:  J Diabetes Investig       Date:  2020-08-08       Impact factor: 4.232

2.  Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy.

Authors:  Wen-Ling Kang; Gao-Si Xu
Journal:  Sci Rep       Date:  2016-01-27       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.